AAV-U6-sasgRNA(scramble)-U6-sasgRNA(scramble)-pCBh-mCherry-W

Research background

This AAV is built for robust expression of a research payload in targeted cells or tissues. AAV-mediated delivery is widely used for stable transgene expression in vivo and in vitro.

Mechanism and expected readouts

Expression outcomes depend on promoter choice, cell state, delivery route, and the biology of the payload. Downstream readouts often include fluorescence imaging, histology, and functional assays matched to the encoded gene.

Expression design and interpretation

Expression is driven by the U6 promoter, which determines where and how strongly the payload is expressed in your system (cell populations defined by the listed promoter). The construct's regulatory logic controls where/when the payload is active; expression is constitutive (no recombinase or inducer required). A built-in reporter/tag supports validation and localization; mCherry provides a red fluorescent protein (Ex ~587 nm / Em ~610 nm) readout for expression, morphology, and targeting validation. The encoded payload is intended to support the stated experimental function (e.g., modulation, sensing, labeling, or control).

Subcellular targeting elements (when present) can bias localization and should be confirmed by imaging in your preparation.

Common research applications

• Cell labeling and anatomical tracing (when paired with appropriate reporters)
• Overexpression or rescue experiments for mechanistic studies
• Tool-building workflows combining expression with physiology or behavior

Experimental considerations

• Plan expression time (often weeks in vivo) according to your tissue and readout
• Validate targeting and expression pattern in pilot experiments
• Include appropriate controls (reporter-only, inactive variants, or sham injection)

Controls and validation

Typical validation includes confirming expression pattern and level, verifying functional activity with an assay matched to the payload (e.g., imaging, electrophysiology, pharmacology, or behavior), and using appropriate negative controls.

• Sales Terms and Conditions (PDF)
• SDS (PDF)

At present, the main purification approaches for rAAV include:

• Ultracentrifugation density-gradient methods, using cesium chloride (CsCl) or iodixanol as the gradient medium;
• Chemical reagent precipitation/extraction methods, mainly using PEG, ammonium sulfate, chloroform, etc.;
• Chromatographic purification methods, primarily based on affinity and ion-exchange principles.

Depending on customers’ different application needs, we can integrate multiple methods to produce high-titer, high-purity, high-quality rAAV viral products.

Can’t find the AAV you need—or require a custom design and packaging service? We offer end-to-end support for diverse research and therapeutic needs, including vector design and cloning, AAV packaging services (serotype/capsid selection and production), QC & characterization (project-appropriate testing and documentation), and library preparation for pooled or library-style workflows (project dependent). Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.